Medical Oncologist Mark Fesen Featured in ASCO Article on Stage IV Breast Cancer

We are thrilled to highlight the incredible work of Dr. Mark Fesen, Medical Oncologist, whose expertise and dedication have led to significant advancements in the field of metastatic breast cancer. His recent involvement in a clinical trial published by the American Society of Clinical Oncology (ASCO) has shed new light on the management and treatment of this challenging disease.

Metastatic breast cancer, also known as stage IV breast cancer, is a complex and aggressive form of cancer that has spread beyond the breast to other parts of the body. It poses immense challenges for patients and healthcare providers alike.

In the ASCO article, titled “Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial,” Dr. Fesen collaborated with a team of esteemed researchers at the University of Kansas Health System in Kansas City, KS.

We express our utmost pride in Dr. Mark Fesen and his significant contributions to this article. The findings of this study are poised to have global and impactful effect on patients diagnosed with stage IV breast cancer.

Find the ASCO article here: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1007